Report
EUR 14.01
For Business Accounts Only
An increasingly favourable environment allows PHARMARON BEIJING to improve to Neutral
The independent financial analyst theScreener just upgraded the general evaluation of PHARMARON BEIJING (CN), a company active in the Biotechnology industry. As regards its fundamental valuation, the title confirms its rating of 2 out of 4 stars while its market behaviour remains as risky. theScreener believes, however, that a more enabling environment allows the title to increase its general evaluation to Neutral. As of the analysis date March 18, 2022, the closing price was HKD 83.35 and its expected value was estimated at HKD 94.35.
Underlying
Pharmaron Beijing Co. Ltd. Class H
Provider
TheScreener
Empowering Investors
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
- Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization. theScreener state of art: We provide
- theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
- For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded.
Other Reports on these Companies
Other Reports from TheScreener
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.